Company Overview
Snapshot
Founded in June 2015 by Giora Weisz, Ron Davidson, Sigal Eli, and Eyal Teichman, Filterlex Medical operates with 1–10 employees. The company has raised $19.49M across 9 funding rounds from 4 investors. In May 2022, Filterlex Medical announced positive results from a first-in-human study for its CAPTIS full-body embolic protection device.
Business overview
Filterlex Medical is a medical device startup focused on developing the Captis, a full-body embolic protection device. This device is designed for easy deployment and retrieval, securely positioning itself in the aorta to protect its surface during TAVI procedures. Its triple-action design provides full-body embolic protection by deflecting, capturing, and removing embolic particles, without requiring additional access or interfering with the procedure workflow. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Medical Treatment & Therapeutics categories, serving healthcare providers in the cardiovascular field.
Strategic signal
In May 2022, Filterlex Medical announced positive results from a first-in-human study for its CAPTIS full-body embolic protection device. This milestone is significant as it validates the device's safety and efficacy in a clinical setting, demonstrating its potential to reduce the risk of stroke during cardiovascular procedures. For investors, this signals strong progress in product development and clinical validation, enhancing the company's market readiness and future commercial prospects in the medical device industry.
Log in to access full profile ›Company Intelligence Q&A
- What is Filterlex Medical's primary product?
- Filterlex Medical's primary product is the Captis, a full-body embolic protection device designed to prevent embolic particles from causing strokes during cardiovascular procedures.
- When was Filterlex Medical founded?
- Filterlex Medical was founded in June 2015.
- What was a key clinical development for Filterlex Medical in 2022?
- In May 2022, Filterlex Medical announced positive results from a first-in-human study for its CAPTIS full-body embolic protection device, indicating successful clinical validation.
- What significant funding did Filterlex Medical receive in December 2021?
- In December 2021, Filterlex Medical was selected to receive funding from the European Innovation Council.